Eledon Pharmaceuticals Inc
$ 3.57
3.18%
11 Jun - close price
- Market Cap 267,070,000 USD
- Current Price $ 3.57
- High / Low $ 3.59 / 3.38
- Stock P/E N/A
- Book Value 1.32
- EPS -0.77
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.35 %
- ROE -0.73 %
- 52 Week High 4.60
- 52 Week Low 1.35
About
Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases and amyotrophic lateral sclerosis (ALS) who require organ or cell transplantation. The company is headquartered in Irvine, California.
Analyst Target Price
$8.20
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-19 | 2025-11-14 | 2025-08-14 | 2025-05-14 | 2025-03-20 | 2024-11-12 | 2024-08-19 | 2024-05-09 | 2024-03-28 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.33 | -0.1 | -0.21 | -0.13 | -0.08 | -0.9456 | -0.32 | -1.06 | -0.34 | -0.29 | -0.35 | -0.4 |
| Estimated EPS | -0.26 | -0.2129 | -0.2414 | -0.22 | -0.3033 | -0.3267 | -0.31 | -0.3 | -0.37 | -0.39 | -0.46 | -0.46 |
| Surprise | -0.07 | 0.1129 | 0.0314 | 0.09 | 0.2233 | -0.6189 | -0.01 | -0.76 | 0.03 | 0.1 | 0.11 | 0.06 |
| Surprise Percentage | -26.9231% | 53.0296% | 13.0075% | 40.9091% | 73.6235% | -189.4399% | -3.2258% | -253.3333% | 8.1081% | 25.641% | 23.913% | 13.0435% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ELDN
2026-06-10 15:40:05
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) is highlighted as one of the hot biotech stocks under $5 to buy, having gained 125.83% year-to-date with analysts seeing further upside. The company recently announced positive updated clinical data for its lead drug, tegoprubart, in type 1 diabetes patients undergoing islet cell transplantation. This data supports the potential for tegoprubart to reshape transplant management, with the company aiming for regulatory guidance by year-end.
2026-06-10 13:22:00
Eledon Pharmaceuticals (NASDAQ: ELDN) announced updated positive results from an investigator-initiated trial evaluating tegoprubart for type 1 diabetes patients undergoing islet cell transplantation. All 12 patients achieved insulin independence and stable graft function, with no severe hypoglycemic episodes or common side effects associated with standard treatments. The company plans to work with the FDA on regulatory guidance for tegoprubart in this indication later this year.
2026-06-10 11:22:05
Eledon Pharmaceuticals announced updated positive results from an investigator-initiated trial of tegoprubart for type 1 diabetes patients undergoing islet cell transplantation. All 12 patients achieved insulin independence and stable islet graft function, with no severe hypoglycemic episodes or adverse side effects commonly associated with other immunosuppressants. The company plans to work with the FDA on regulatory guidance for tegoprubart in islet cell transplantation.
2026-06-09 02:40:05
Eledon Pharmaceuticals' stock surged after reporting positive results from a type 1 diabetes study. All 12 patients in the trial achieved insulin independence and maintained stable islet graft function with the company's investigational anti-CD40L antibody, tegoprubart. These findings were presented at the American Diabetes Association 86th Scientific Sessions.
2026-06-08 15:09:13
Eledon Pharmaceuticals announced updated positive data from an investigator-initiated trial of tegoprubart in Type 1 Diabetes patients undergoing islet transplantation at UChicago Medicine. All 12 patients achieved insulin independence and significantly improved HbA1c levels, with no severe hypoglycemic episodes post-transplant. The tegoprubart-based immunosuppression regimen was well-tolerated and avoided the toxicities associated with standard tacrolimus-based regimens.
2026-06-08 13:08:54
Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) shares surged after reporting positive results from a type 1 diabetes trial. All 12 patients in the study achieved insulin independence and significantly improved HbA1c levels, with no severe hypoglycemic episodes post-transplant. The trial evaluated tegoprubart as part of an immunosuppression regimen for patients undergoing allogeneic islet cell transplantation.
